Description

Beinaglutide is a GLP-1 receptor agonist that mimics endogenous glucagon-like peptide-1 to regulate glucose metabolism, insulin secretion, and appetite. It has been widely studied in obesity, metabolic syndrome, and type 2 diabetes models.

This product comes in a pre-filled injection pen containing 2.1ml of solution (4.2mg, 42,000U). Manufactured by Shanghai Rennai Biopharmaceutical Co., Ltd., it is NMPA-approved under S20230042 and intended only for laboratory use.

?? Strictly for research use only. Not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Beinaglutide is a recombinant human GLP-1 analog that binds to GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. In research, it is employed to investigate:

• Glucose metabolism and insulin regulation

• Weight loss and appetite modulation pathways

• Type 2 diabetes mechanisms

• Gut-brain axis signaling

• GLP-1 receptor pharmacodynamics

Safety & Handling

• Use Restriction: For laboratory research use only. Not for clinical, diagnostic, or veterinary purposes.

• Handling: Use gloves and protective lab equipment. Avoid direct contact.

• Storage: Keep refrigerated at 2–8°C. Do not freeze. Avoid exposure to light.

• Disposal: Dispose of according to institutional biosafety guidelines.

Research Use Disclaimer

This product is intended exclusively for laboratory research purposes. It is not approved for use in humans or animals. Any misuse may result in health or legal risks. Handle in compliance with institutional biosafety protocols.